156 related articles for article (PubMed ID: 10207335)
1. Meta-analysis and adverse drug reactions.
Mittmann N; Liu BA; Knowles SR; Shear NH
CMAJ; 1999 Apr; 160(7):987-8. PubMed ID: 10207335
[No Abstract] [Full Text] [Related]
2. How should we react to adverse drug reactions?
Ferner RE; Beard K
Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818
[No Abstract] [Full Text] [Related]
3. Pitfalls in meta-analyses on adverse events reported from clinical trials.
Huang HY; Andrews E; Jones J; Skovron ML; Tilson H
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1014-20. PubMed ID: 21858897
[TBL] [Abstract][Full Text] [Related]
4. Some concerns about adverse event reporting in randomized clinical trials.
Yazici Y
Bull NYU Hosp Jt Dis; 2008; 66(2):143-5. PubMed ID: 18537786
[TBL] [Abstract][Full Text] [Related]
5. Reporting adverse events in randomized controlled trials.
Nuovo J; Sather C
Pharmacoepidemiol Drug Saf; 2007 Mar; 16(3):349-51. PubMed ID: 16998947
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug reaction (ADR).
Elizabeth KE
Indian Pediatr; 2007 Jul; 44(7):548; author reply 548-9. PubMed ID: 17684311
[No Abstract] [Full Text] [Related]
7. Research methods in drug surveillance.
Engel RR; Grohmann R; Rüther E; Hippius H
Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
[TBL] [Abstract][Full Text] [Related]
8. Adverse drug reactions and avalanches: life at the edge of chaos.
Frattarelli DA
J Clin Pharmacol; 2005 Aug; 45(8):866-71. PubMed ID: 16027396
[TBL] [Abstract][Full Text] [Related]
9. Propensity score methods in drug safety studies: practice, strengths and limitations.
Wang J; Donnan PT
Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
[No Abstract] [Full Text] [Related]
10. Drug safety--important to us all!
Böttiger LE
J Intern Med; 2001 Oct; 250(4):269-70. PubMed ID: 11576314
[No Abstract] [Full Text] [Related]
11. Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: the case of rosiglitazone.
Hernandez AV; Walker E; Ioannidis JP; Kattan MW
Am Heart J; 2008 Jul; 156(1):23-30. PubMed ID: 18585493
[TBL] [Abstract][Full Text] [Related]
12. [Placebo effects and adverse effects in clinical trials].
Weihrauch TR
Med Klin (Munich); 2000 May; 95(1 Spec No):23-30. PubMed ID: 10851845
[TBL] [Abstract][Full Text] [Related]
13. Medication-related adverse reactions and the elderly: a literature review.
Atkin PA; Shenfield GM
Adverse Drug React Toxicol Rev; 1995; 14(3):175-91. PubMed ID: 7492703
[No Abstract] [Full Text] [Related]
14. Individual patient meta-analysis--rewards and challenges.
van Walraven C
J Clin Epidemiol; 2010 Mar; 63(3):235-7. PubMed ID: 19595573
[No Abstract] [Full Text] [Related]
15. [Adverse drug reactions definitions and terminology].
Rabinovitz H; Berkowitch M; Golik A; Shani S
Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
[TBL] [Abstract][Full Text] [Related]
16. Safety reporting in randomized clinical trials - a need for improvement.
Yazici Y
Bull NYU Hosp Jt Dis; 2009; 67(2):209-10. PubMed ID: 19583556
[TBL] [Abstract][Full Text] [Related]
17. [Statistics--lying, but properly].
Bias R
Wien Med Wochenschr; 1998; 148(1-2):30-1. PubMed ID: 9642762
[No Abstract] [Full Text] [Related]
18. Submitting reports of adverse drug reactions to AJHP.
Thompson CA
Am J Hosp Pharm; 1994 Oct; 51(19):2358. PubMed ID: 7847399
[No Abstract] [Full Text] [Related]
19. Adverse drug reactions: moving from chance to science.
Haller C; James LP
Clin Pharmacol Ther; 2011 Jun; 89(6):761-4. PubMed ID: 21593747
[No Abstract] [Full Text] [Related]
20. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
